Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Healthcare Biotechnology Medical Instruments & Supplies
Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Spectral Medical Inc
Bullboard Posts
User Avatar Image
(132)
•••
Comment by Stocktreeon Dec 15, 2015 8:45am
50 Views
Post# 24384830

RE:The abstract from Ronco is interesting.......

RE:The abstract from Ronco is interesting.......
Incorrect, misleading...

I repeat, Toraymyxin deviced not approved in Canada

Published by Spectral Medical in November 2015:

"Toraymyxin was approved for therapeutic use in Japan in 1994 and Europe in 2002 and has been used safely and effectively in more than 100,000 patients to date. In March 2009 and November 2010 respectively, Spectral obtained the exclusive development and commercial rights in the U.S. and Canada for Toraymyxin."

and in September 2015

"The stand-alone pump is also designed to provide an open platform for other hemoperfusion cartridges and to deliver continuous renal replacement therapy ("CRRT") when indicated. Approval of this instrument by Health Canada is anticipated during the fourth quarter of 2015, with 510K approval in the United States targeted for the first quarter of 2016."
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities